SCHEMBL5618288

SCHEMBL5618288

CNc1nccn2c(-c3ccc(C(=O)N4CCOCC4)s3)cnc12

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 7/20 0.55
▸ FLT3 P36888 3/20 0.52
▸ HPGD P15428 1/20 0.46
▸ MKNK1 Q9BUB5 2/20 0.44
▸ MKNK2 Q9HBH9 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ ERN1 O75460 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ TTK P33981 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5618766 0.89 KDM4E (0.47) MAPKAPK5FLT3MKNK1MKNK2NPC1
SCHEMBL5618266 0.84 L3MBTL3 (0.51) MAPKAPK5FLT3HPGDALDH1A1TTK
SCHEMBL14573309 0.83 MAPKAPK5 (0.50) MAPKAPK5FLT3FYNTTKADORA3
SCHEMBL5618395 0.82 FLT3 (0.49) MAPKAPK5FLT3MKNK1MKNK2NPC1
SCHEMBL5617937 0.80 FLT3 (0.47) MAPKAPK5FLT3TTKADORA3
SCHEMBL5618210 0.79 MAPKAPK5 (0.39) MAPKAPK5FLT3ALDH1A1MAPTTTK
SCHEMBL5619095 0.73 FLT3 (0.49) MAPKAPK5FLT3HRH3
SCHEMBL5618824 0.73 FLT3 (0.53) MAPKAPK5FLT3ALDH1A1MAPTTTK
SCHEMBL14573306 0.72 AKT3 (0.44) MAPKAPK5FLT3TTK
SCHEMBL2068531 0.71 MAPKAPK5 (1.00) MAPKAPK5FLT3FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US claimed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 MAPKAPK5 29/4885FLT3 216/4885HPGD 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback